Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
April 2016
-
In The News
Beautiful Medicine: Rediscover the Power of Nature’s Exquisite Complexity
-
Press Release
Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's® nephrology indication
Sandoz' epoetin alfa product offering has already generated more than 400,000[1] patient years of experience worldwide EC approval expands Sandoz biosimilar offering to the healthcare community… -
Press Release
Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITP
EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies Two formulations approved: once-daily… -
Featured News
Novartis and Red Cross partner to tackle chronic diseases in refugee populations
Novartis is partnering with the International Committee of the Red Cross (ICRC) to improve care and treatment for Syrian refugees in Lebanon suffering from chronic diseases.
-
Story From Our Labs
Hooked on science, Jay Bradner becomes top researcher at Novartis
New NIBR President Jay Bradner shares on drug discovery, his leadership style and what’s next for his career in biomedical research.
-
Press Release
New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless...
New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless of prior heart…
March 2016
-
Press Release
Novartis publishes updated 2015 segment financials reflecting new division structure
Updated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY… -
In The News
CRISPR genome editing fuels cancer drug discovery
The better we know the molecular underpinnings of a disease, the better the odds of discovering new medicines for patients. CRISPR is changing the way medicines target cancer and other diseases. -
Story Patient Perspectives
Dealing with psoriasis
British actor and comedian Toby Hadoke talks about his struggles with psoriasis.
-
Story From Our Labs
When tiny brains are best for brain research
Zebrafish imaging sheds light on human neurological conditions.
-
Press Release
Novartis' Cosentyx superior to Stelara in delivering long-lasting skin clearance (PASI 90) for psoriasis patients at 52 weeks
New data at AAD 2016 shows Cosentyx® is significantly more efficacious than Stelara in sustaining skin clearance (PASI 90 to PASI 100) at 52 weeks[1] Cosentyx delivered and sustained skin…
